Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - Κυστική ίνωση - Άλλα προϊόντα του αναπνευστικού συστήματος - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 και 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 και 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - Κυστική ίνωση - Άλλα προϊόντα του αναπνευστικού συστήματος - orkambi δισκία ενδείκνυνται για τη θεραπεία της κυστικής ίνωσης (κι) σε ασθενείς ηλικίας 6 ετών και άνω που είναι ομόζυγο για τη μετάλλαξη f508del στο γονίδιο cftr. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - Κυστική ίνωση - Άλλα προϊόντα του αναπνευστικού συστήματος - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - Κυστική ίνωση - Άλλα προϊόντα του αναπνευστικού συστήματος - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

vertex pharmaceuticals (ireland) limited,ireland 28-32 pembroke street upper, d02 ek84 dublin 2 - ivacaftor - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 150mg/tab - ivacaftor 150mg - ivacaftor

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

vertex pharmaceuticals (ireland) limited,ireland 28-32 pembroke street upper, d02 ek84 dublin 2 - ivacaftor; tezacaftor - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 100 mg/ 150 mg - ivacaftor 150mg; tezacaftor 100mg - ivacaftor and tezacaftor

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

vertex pharmaceuticals (ireland) limited,ireland 28-32 pembroke street upper, d02 ek84 dublin 2 - ivacaftor; tezacaftor; elexacaftor - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (75+50+100)mg/tab - ivacaftor 75mg; tezacaftor 50mg; elexacaftor 100mg - ivacaftor, tezacaftor and elexacaftor

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

vertex pharmaceuticals (ireland) limited,ireland 28-32 pembroke street upper, d02 ek84 dublin 2 - lumacaftor; ivacaftor - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (100+125) mg/tab - lumacaftor 100mg; ivacaftor 125mg - ivacaftor and lumacaftor

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

vertex pharmaceuticals (ireland) limited,ireland 28-32 pembroke street upper, d02 ek84 dublin 2 - lumacaftor; ivacaftor - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (200+125) mg/tab - lumacaftor 200mg; ivacaftor 125mg - ivacaftor and lumacaftor

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

vertex pharmaceuticals (ireland) limited,ireland 28-32 pembroke street upper, d02 ek84 dublin 2 - lumacaftor; ivacaftor - granules (ΚΟΚΚΙΑ) - (100+125) mg/tab - lumacaftor 100mg; ivacaftor 125mg - ivacaftor and lumacaftor